Merck

March 1, 2017

Letermovir Helps Prevent Post-transplant Viral Infections, Clinical Trial Shows

News

Lymphoma patients who obtain stem cell transplants may soon have a new therapy to ward off cytomegalovirus (CMV) infections, the results of a Phase 3 clinical trial indicate. In contrast ... Read more

April 20, 2016April 20, 2016

FDA Approves Breakthrough Therapy Designation for Hodgkin’s Lymphoma Treatment Keytruda

News

The FDA has granted Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), Breakthrough Therapy Designation (BTD) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin’s lymphoma (cHL). The FDA previously granted BTD ... Read more

February 2, 2016May 13, 2016

Researchers Develop Promising Cancer Drug to Treat Mantle Cell Lymphoma

News

Australian researchers from the Center Therapeutics CRC (CTx) have developed a promising cancer drug that can be used to treat mantle cell lymphoma. The drug has now been licensed to the ... Read more

December 14, 2015

Last Week’s Top 3 Most Read Posts About Lymphoma

Read the Articles Here: Treatment-Naive Follicular Lymphoma Patients Respond Well to Ibrutinib Combo Therapy Non-Hodgkin Lymphoma Study of Novartis’ T-cell Therapy Shows Early Efficacy New Non-Hodgkin Lymphoma Drug Combo Trial ... Read more

December 8, 2015May 13, 2016

New Non-Hodgkin Lymphoma Drug Combo Trial Launched by Amgen, Merck

News

Amgen and Merck are partnering to support a Phase 1b/3 clinical trial evaluating a cancer immunotherapy combination in patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL). The ... Read more